Three generic pharmaceutical manufacturers, Taro Pharmaceuticals USA, Sandoz, the biosimilars and generics business of Novartis and Apotex Corp, have agreed to pay a total of $447.2 million to resolve alleged violations of the False Claims Act arising from conspiracies to fix the price of various generic drugs. 2 October 2021
Danish diabetes care giant Novo Nordisk has reached an agreement in principle to settle the previously disclosed securities class action litigation pending in the Federal District Court of New Jersey, USA, with the company’s US traded shares dipping 1.6% to $100.63 on the news. 25 September 2021
Court filings show that Canada-headquartered Bausch Health has agreed to pay $300 million to settle an antitrust suit related to diabetes med Glumetza (metformin hydrochloride). 13 September 2021
Shares Ireland-incorporated Endo International rose almost 18% to $2.10 in after-hours trading yesterday, after the company announced a $50 million settlement to exit a New York opioid trial. 10 September 2021
In the USA, an appeals court has overthrown an earlier ruling against Gilead Sciences, a decision which could save the company $1.2 billion in fines. 28 August 2021
While the suspension of patent extensions in Brazil could lead to lower drug prices and cheaper generic drugs, this move may deter large biopharma companies from marketing innovative drugs in Brazil in the future, says data and analytics company. 13 August 2021
The Indian subsidiary of Anglo-Swedish pharma major AstraZeneca has reported a 45.03% decline in its net profit to $1.37 million for the June ended fiscal quarter. 9 August 2021
The UK Competition and Markets Authority (CMA) has provisionally found that US pharma giant Pfizer and its UK distributor Flynn Pharma, abused their dominant positions to overcharge the NHS for vital anti-epilepsy drugs, after reassessing the case. 6 August 2021
The Federal Trade Commission (FTC) has expressed its disappointment at a Supreme Court decision relating to AndroGel (testosterone gel), a prescription medicine used to treat the symptoms of testosterone deficiency. 2 August 2021
The UK’s Competition and Markets Authority (CMA) has imposed over £100 million ($139 million) in fines after Advanz inflated the price of thyroid tablets, causing the National Health Service (NHS) and patients to lose out. 30 July 2021
A California federal jury hit Novartis with a $177.8 million verdict Thursday for selling a skin cancer drug that infringes two patents owned by Daiichi Sankyo US subsidiary Plexxikon, rejecting Novartis' arguments that the patents are invalid and awarding the entire sum the plaintiff sought. 23 July 2021
USA-based healthcare giant Johnson & Johnson, together with three major drug distributors, are ready to agree to a $26 billion settlement in connection with lawsuits over the ongoing opioid epidemic. 21 July 2021
An Expert View on the pros and cons of intellectual property (IP) protections in the pharmaceutical sector from White & Case partners' competition lawyer, James Killick, chair of the firm’s IP practice, Anita Varma, and associate and member of the Global Competition practice group, Alexander Krois. 20 July 2021
Following investigations from the UK’s Competition and Markets Authority (CMA), a fine of around £260 million ($360 million) has been imposed on several pharmaceutical firms, due to competition law breaches. 15 July 2021
Leading UK scientists have warned the government that patent protections on COVID-19 vaccines threaten the security of the country’s vaccination program and could lead to further lockdowns after July 19, when restrictions are currently due to lift. 12 July 2021
Troubled drugmaker Purdue Pharma has stepped a little closer to emerging from bankruptcy, after securing the backing of 15 states for a settlement related to claims arising from the ongoing opioid crisis. 9 July 2021
In March 2019, the Hungarian authorities ordered local drugmaker Pharma Expressz to stop its practice consisting in placing on the market in Hungary, without complying with the formalities laid down in Hungarian law in that regard, of medicines which have been granted marketing authorization by another European Union member state as a medicinal product and which are available without medical prescription. 8 July 2021
The Indian subsidiary of Anglo-Swedish pharma major AstraZeneca has filed a writ petition before the Delhi High Court challenging a demand notice from India's National Pharmaceutical Pricing Authority (NPPA) alleging overcharging of Tagrisso (osimertinib) tablets by the company. 1 July 2021
US healthcare giant Johnson & Johnson is to pay $230 million to the state of New York in a settlement over accountability for the opioid epidemic ahead of a court case due to begin this week. 28 June 2021
The European Commission has approved, under the EU Merger Regulation, the acquisition of joint control of privately-held Danish drugmaker Leo Pharma by Nordic Capital Fund X of Jersey and Leo Foundation of Denmark. Leo Pharma develops, manufactures and markets pharmaceutical products. 25 June 2021
Sino-American oncology company BeOne Medicines, until now known as BeiGene, has entered into a settlement agreement with MSN Pharmaceuticals and MSN Laboratories Private resolving patent litigation related to MSN’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Brukinsa (zanubrutinib) in the USA. 25 November 2024
The European Union's antitrust enforcer hit Israeli drugmaker Teva Pharmaceutical Industries (NYSE: TEVA) with a 463 million-euro ($502 million) fine Thursday for launching a smear campaign against a rival multiple sclerosis drug and misusing the patent system to thwart the competitor's attempt to entering the market. 31 October 2024
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
GSK has reached a settlement with 10 plaintiff firms, resolving 93% of the Zantac (ranitidine) product liability cases it faced in state courts across the USA. 10 October 2024
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
Texas Attorney General Ken Paxton has filed a lawsuit against major pharmaceutical companies, including Eli Lilly (NYSE: LLY), alleging a conspiracy to artificially inflate the prices of insulin by up to 1,000%. 7 October 2024
Bristol Myers Squibb has scored a major legal victory as a judge in New York dismissed a $6.4 billion lawsuit related to its acquisition of cancer company Celgene. 5 October 2024
The US Department of Health and Human Services (HHS) has released final guidance for the second cycle of Medicare drug price negotiations. 3 October 2024
The Pharmaceutical Research and Manufacturers of America (PhRMA) is continuing its legal challenge against the US government’s drug pricing reforms. 24 September 2024
On Friday, the USA’s Federal Trade Commission (FTC) brought action against the three largest prescription drug benefit managers (PBMs) - Caremark Rx, Express Scripts (ESI), and OptumRx 23 September 2024
In a lawsuit filed in federal court in Missouri, USA, Health insurer Cigna (NYSE: CI) and its pharmacy benefit manager (PBM) Express Scripts demanded that the Federal Trade Commission (FTC) retract its July 2024 report. 18 September 2024
Several pharma companies that had moved the Delhi High Court against the government’s recent notification banning 156 fixed-dose combination (FDC) drugs have got a breather. 10 September 2024
Glenmark Pharmaceuticals has agreed to pay $25 million, based on its ability to pay, to resolve its alleged liability under the False Claims Act for conspiring to fix the price of a generic drug, the US Department of Justice announced. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Regeneron Pharmaceuticals has filed a lawsuit against Sandoz, alleging that its biosimilar to Eylea (aflibercept) infringes certain patents. 29 August 2024